A carregar...
Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer
Immune-checkpoint inhibitors (ICI), specifically inhibitors of programmed death ligand-1 (PD-L1) and receptor (PD-1) are the new standard of care for the treatment of patients with advanced non-small cell lung cancer (NSCLC) in front line setting as monotherapy or along with chemotherapy. Many of th...
Na minha lista:
| Publicado no: | BMJ Case Rep |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7449356/ https://ncbi.nlm.nih.gov/pubmed/32843385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-236101 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|